Psychedelic medications, including psilocybin, have recently received breakthrough designation by the US Food and Drug Administration (FDA) for other psychiatric indications. Although no formal clinical trials have yet investigated psychedelic substances for the treatment of PTSD, the available evidence warrants such an investigation. The present study aims to investigate the effect of psilocybin on treatment-resistant PTSD.
Scientists believe that psilocybin can help to reduce symptoms of PTSD by inhibiting the reuptake of serotonin. This helps to increase levels of serotonin in the brain, which can have an antidepressant effect. In addition, psilocybin can also help to reduce anxiety and fear.
Although no formal clinical trials have yet investigated psychedelic substances for the treatment of PTSD, the available evidence warrants such an investigation. The present study aims to investigate the effect of psilocybin on treatment-resistant PTSD.